MENLO PARK, Calif.

门洛帕克，加利福尼亚州

,

，

May 12, 2025

2025年5月12日

/PRNewswire/ -- GRAIL, Inc. (Nasdaq:

/PRNewswire/ -- GRAIL, Inc. (纳斯达克:

GRAL

GRAL

), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri.

），一家致力于在癌症可以治愈时及早检测的医疗保健公司，今天宣布与全国领先的医疗实践和系统网络软件和服务提供商athenahealth建立新的合作伙伴关系。此次合作将整合GRAIL的Galleri检测订单。

®

®

multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution..

将多癌症早期检测（MCED）测试整合到athenaCoordinator Core中，这是一项旨在帮助简化医疗机构实验室订单传输和护理协调的服务。该整合将通过athenahealth领先的基于云的电子健康记录（EHR）解决方案athenaOne提供。

Integration with athenaCoordinator Core will allow over 160,000 U.S. clinicians on the athenahealth network to opt in to more seamlessly order Galleri directly in the EHR, reducing additional ordering steps. After the clinician's order is placed, the patient can take the Galleri test kit to a blood draw appointment.

与athenaCoordinator核心系统的集成将使athenahealth网络上超过16万名美国临床医生可以选择更无缝地直接在电子健康记录（EHR）中下单订购Galleri，减少额外的订购步骤。临床医生下单后，患者可以将Galleri测试套件带到抽血预约处进行检测。

The Galleri test results will be made available automatically in the patient chart, reducing manual entry and administrative burden for the clinician's practice..

Galleri测试结果将自动显示在患者图表中，减少了临床医生手动输入和管理的负担。

'Cancer remains a public health crisis. There is a clear need to transform the way we screen for cancer while still asymptomatic, when it can be more easily treated,' said

“癌症仍然是一个公共卫生危机。显然，我们需要改变筛查癌症的方式，尤其是在癌症无症状、更容易治疗的时候。”

Josh Ofman

乔什·奥夫曼

, MD, MSHS, president at GRAIL. 'Integrating with athenaCoordinator Core will help simplify the Galleri test ordering process as part of routine exams and help increase patient access to multi-cancer early detection to screen for some of the deadliest cancers before they become symptomatic.'

医学博士、MSHS、GRAIL总裁表示：“与athenaCoordinator Core的整合将有助于简化Galleri测试在常规检查中的下单流程，并帮助增加患者获取多癌症早期检测的机会，以便在一些最致命的癌症出现症状之前进行筛查。”

Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique 'fingerprint' of cancer. With a single blood draw, the Galleri test screens for the 'fingerprint' of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today.

癌症在体内生长时会将DNA释放到血液中。这些DNA片段就像癌症的独特“指纹”。通过一次抽血，Galleri测试能够在许多最致命的癌症出现症状之前筛查其“指纹”，包括目前尚无推荐筛查方法的癌症。

It can also provide doctors with information on the cancer's origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings..

它还可以为医生提供有关癌症起源的信息，以帮助预测与癌症信号相关的组织类型或器官。Galleri测试仅为处方使用，推荐给癌症风险较高的成年人，例如50岁及以上的人群，并且应作为常规癌症筛查的补充手段。

About GRAIL

关于GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages.

GRAIL是一家医疗保健公司，其使命是早期发现癌症，以便能够治愈。GRAIL致力于通过利用下一代测序技术、大规模人群临床研究以及最先进的机器学习、软件和自动化技术，来检测和识别多种致命癌症的早期阶段，从而减轻全球癌症负担。

GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in .

GRAIL的靶向甲基化平台可以支持筛查和精准肿瘤学的连续护理，包括对有症状患者的多癌症早期检测、风险分层、微小残留病检测、生物标志物亚型分析、治疗和复发监测。 GRAIL总部位于 。

Menlo Park, CA

门洛帕克，加利福尼亚州

with locations in

地点位于

Washington, D.C.

华盛顿特区

,

，

North Carolina

北卡罗来纳州

, and the

，以及

United Kingdom

英国

.

。

For more information, visit

欲了解更多信息，请访问

grail.com

grail.com

.

。

About Galleri

关于Galleri

®

®

The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique 'fingerprint' of cancer, to help screen for some of the deadliest cancers that don't have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable.

Galleri多癌症早期检测测试是一种积极的癌症筛查工具。通过简单的抽血，Galleri测试可以识别癌细胞释放的DNA，这些DNA可以作为癌症的独特“指纹”，帮助筛查一些目前尚无推荐筛查方法的最致命癌症，例如胰腺癌、食道癌、卵巢癌、肝癌等。* Galleri测试可以在一个人出现症状之前进行癌症筛查，此时癌症可能更容易治疗且有可能治愈。

The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening.

Galleri测试可以指示癌症的起源，为医疗保健提供者提供进一步探索的路线图。Galleri测试需要由有执照的医疗保健提供者开具处方，并且应该作为推荐的癌症筛查（如乳腺X光检查、结肠镜检查、前列腺特异性抗原（PSA）测试或宫颈癌筛查）的补充使用。

The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older..

Galleri测试推荐给癌症风险较高的成年人，例如50岁或以上的人群。

For more information, visit

欲了解更多信息，请访问

galleri.com

galleri.com

.

。

Sensitivity in

灵敏度

study

学习

participants with –

参与者具有——

Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Esophagus cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV). Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV). Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV)..

胰腺癌：总体83.7%（I期61.9%，II期60.0%，III期85.7%，IV期95.9%）。食道癌：总体85.0%（I期12.5%，II期64.7%，III期94.7%，IV期100%）。卵巢癌：总体83.1%（I期50.0%，II期80.0%，III期87.1%，IV期94.7%）。肝/胆管癌：总体93.5%（I期100%，II期70.0%，III期100%，IV期100%）。

Important Galleri Safety Information

重要画廊安全信息

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located.

Galleri 检测适用于癌症风险较高的成年人，例如 50 岁及以上的人群。该检测不能发现所有癌症，应作为医疗保健提供者推荐的常规癌症筛查检测的补充。Galleri 检测旨在检测癌症信号并预测癌症信号在体内的位置。

Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment..

不建议孕妇、21岁或以下的人群以及正在接受癌症治疗的个体使用该测试。

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer..

结果应由医疗保健提供者结合病史、临床体征和症状进行解读。未检测到癌症信号的检测结果并不能排除癌症。检测到癌症信号的检测结果需要通过医学上已确立的程序（例如影像学检查）进行确认性诊断评估以确认癌症。

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur.

如果通过进一步检测未确认癌症，这可能意味着没有癌症，或者检测不足以发现癌症，包括由于癌症位于身体的不同部位。假阳性（在没有癌症时检测到癌症信号）和假阴性（在有癌症时未检测到癌症信号）的检测结果确实会发生。

.

。

Rx only.

仅处方药。

Laboratory/Test Information

实验室/测试信息

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration.

GRAIL临床实验室根据1988年的《临床实验室改进修正案》（CLIA）获得认证，并由美国病理学家学会认可。Galleri测试由GRAIL开发，并且其性能特征已由GRAIL确定。Galleri测试尚未获得食品和药物管理局的批准或认可。

The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes..

GRAIL临床实验室受CLIA监管，进行高复杂性检测。Galleri测试旨在用于临床目的。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as 'aim,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'should,' 'would,' or 'will,' the negative of these terms, and other comparable terminology.

本新闻稿包含前瞻性陈述。在某些情况下，您可以通过诸如“目标”、“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“可能”、“计划”、“潜力”、“预测”、“应该”、“会”、“将”等前瞻性词语，这些术语的否定形式以及其他类似术语来识别这些陈述。

These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations about or projections ease of ordering Galleri, potential increases in patient access, clinical impact, technology, clinical and real world studies, regulatory compliance, potential market opportunity, anticipated growth strategies, and other topics..

这些前瞻性陈述受与我们相关的风险、不确定性和假设的影响，可能包括对订购Galleri的便捷性、患者获取途径的潜在增加、临床影响、技术、临床和真实世界研究、法规合规性、潜在市场机会、预期增长战略及其他主题的预期或预测。

These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled 'Risk Factors' in our Annual Report on Form 10-Q for the period ended .

这些声明仅为基于我们当前对未来事件和趋势的预期和预测所做的预测。存在一些重要因素，可能导致我们的实际结果、活动水平、表现或成就与前瞻性声明中明示或暗示的内容存在重大且不利的差异，这些因素包括在我们截至某日的10-Q表年度报告中“风险因素”部分讨论的那些因素及众多相关风险。

March 31, 2025

2025年3月31日

and our Form 10-K for the period ended

截至期末的10-K表格

December 31, 2024

2024年12月31日

(the 'Form 10-K'). Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make..

（“表格10-K”）。此外，我们处在一个动态且快速变化的环境中。新的风险不时出现。我们的管理层无法预测所有风险，也无法评估所有因素对我们业务的影响，或任何因素或因素组合可能导致实际结果、活动水平、业绩或成就与我们可能作出的任何前瞻性陈述中包含的内容存在重大不利差异的程度。

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements.

前瞻性声明涉及未来，因此存在固有的不确定性、风险和难以预测的环境变化，其中许多因素超出我们的控制范围。尽管我们认为前瞻性声明中表达或暗示的预期和预测是合理的，但我们无法保证未来的结果、活动水平、业绩或成就。

Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events..

我们的实际结果和财务状况可能与前瞻性陈述中所示的内容有重大差异。除非法律要求，我们没有义务在本新闻稿发布之后更新任何前瞻性陈述，以使我们之前的陈述符合实际结果或修订后的预期，或反映新信息或未预见事件的发生。

SOURCE GRAIL, Inc.

源圣杯公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用